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THE APPLICATION OF BAYESIAN METHODS TO EVALUATE
THE IMPACT OF TIME-DELAY ON THE COST-EFFECTIVENESS
OF PRIMARY ANGIOPLASTY FOR ACUTE MYOCARDIAL
INFARCTION
Palmer SJ,Asseburg C, Bravo-Vergel Y, Fenwick E, Sculpher M
University of York,York, North Yorkshire, UK
OBJECTIVES: To apply Bayesian approaches to evaluate the
impact of time-delay on the cost-effectiveness of primary angio-
plasty versus hospital-administered thrombolysis for patients
with acute myocardial infarction. METHODS: A probabilistic
model was developed to evaluate the life-term cost-effectiveness
of primary angioplasty. A health service perspective was adopted
with outcomes estimated using Quality-Adjusted Life Years
(QALYs). Evidence on short-term event rates was obtained by
updating a recent meta-analysis of randomised trials comparing
angioplasty with thrombolysis (Lancet 2003; 361:13–20). Data
from 22 trials were combined using Bayesian hierarchical mod-
eling and meta-regression. This approach enabled the simulta-
neous estimation of posterior distributions and correlation
structure for: 1) major cardiovascular events including death, re-
infarction and stroke, and 2) different time endpoints (4–6 weeks
and 6 months). The impact of PCI time-delay to treatment was
analysed using mean time delay compared to thrombolysis as a
covariate of the random effects model. Long-term costs and
QALYs were estimated using a Markov model populated from
UK registry data. RESULTS: Based on the average time-delay
reported in the trials (54 minutes), primary angioplasty resulted
in a mean gain of 0.29 QALYs and an additional cost of £2680
compared to thrombolysis. The associated incremental cost-
effectiveness ratio (ICER) was £9241 per QALY. At a threshold
of £20,000 per QALY there was a 90% probability that primary
angioplasty was cost-effective. Adjusting the time-delay resulted
in considerable variation in the cost-effectiveness estimates. 
For a shorter delay of 30-minutes the ICER was £6,850 per
QALY; increasing the time-delay to 90-minutes resulted in a
marked increase in the ICER to £64,750 per QALY (98% and
36% probability cost-effective at £20k, respectively). CON-
CLUSIONS: This study demonstrates the policy importance of
time-delay when considering the cost-effectiveness of primary
angioplasty, and the advantages of using Bayesian approaches to
model multiple endpoints, treatment effects and baseline event
rates.
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OBJECTIVES: Genital herpes (GH) is widespread, psychologi-
cally disabling and costly. GH is characterized by episodic out-
breaks of genital and perigenital vesicles and ulcers, and is one
of the most prevalent sexually transmitted diseases in the world
today. The seroprevalence of herpes simplex virus (HSV) type-2
ranges from 13% to 40% in the United States and from 7% to
16% in Europe. Often GH is not adequately treated, with con-
sequences on beneﬁts and patients’ well being, and potentially
important economic repercussions. GH patients play an impor-
tant role in decision-making for their management strategies, and
their preferences can be crucial to improve treatment outcomes
and resource allocation. This study evaluated patients’ prefer-
ences in GH treatment. METHODS: Preferences were elicited
from 157 patients, recruited from the Harris Poll panel, who
completed an online Discrete Choice Experiment (DCE) ques-
tionnaire. DCE data was analysed using multinomial logit regres-
sion models to estimate respondents’ preferences for GH medical
treatment. RESULTS: Respondents, from the US (87.9%) and
UK (12.1%), had a median age of 43 years (21–65), and 83.4%
were women. Overall, respondents preferred medical treatment
to no treatment of GH, with suppressive treatment preferred 
to episodic, assuming everything else equal. Willingness to 
pay (WTP) was $38.2/month for episodic treatment and
$60.6/month for suppressive treatment, assuming everything else
equal. Furthermore, respondents were WTP $56.6/month for a
1% reduction in the “chance of a GH recurrence” in 12 months.
In terms of treatment, respondents’ preferences indicated that
generally patients preferred the treatment they currently receive.
Globally, more patients would choose to be treated (74.3%) than
those actually treated (56.2%). CONCLUSIONS: Patients prefer
suppressive treatment of GH. Such preferences are inﬂuenced by
experience, knowledge and awareness of available options. The
estimated model suggests that more patients than those actually
receiving drug therapies would consider being treated.
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OBJECTIVE: With an estimated prevalence in Canada between
206,000 and 280,000 persons infected with the virus, persons
with hepatitis B typically progress through increasingly severe
disease states before death. The objective was to estimate pref-
erences (ratings and utility weights) for six hepatitis B-related
disease states among uninfected persons. METHODS: Three
hepatologists characterized the typical effects of symptoms on
health-related quality of life in terms of symptoms, frequency of
tests, hospitalizations, procedures, and dimensions of health such
as pain, ability for self-care, activities of daily living, psycholog-
ical well-being and future outlook. From a convenience sample
of 100 uninfected persons in Canada, we elicited ratings using a
visual analog scale based on a ‘feeling’ thermometer and stan-
dard gamble utility weights using probability wheels with 2-color
pie charts for the relative probabilities of perfect health and
death. RESULTS: The mean age was 42 years (standard devia-
tion (SD): 14.8, range: 18 to 80 years) and 29% were male.
Mean utilities were: 0.80 (95% conﬁdence interval (CI): 0.76;
0.83) for chronic hepatitis B; 0.79 (CI: 0.75; 0.83) for compen-
sated cirrhosis; 0.41 (CI: 0.35; 0.46) for decompensated cirrho-
sis; 0.69 (CI: 0.65; 0.74) for the ﬁrst year after liver transplant;
0.77 (CI: 0.73; 0.80) for subsequent years after liver transplant;
and, 0.45 (CI: 0.40; 0.51) for hepatocellular carcinoma. The
values using the visual analog scale were lower than utilities
elicited using the standard gamble, but the relative ranking of
each health state did not change. CONCLUSION: All six hepati-
tis B-related health states are associated with substantial loss of
quality-of-life, with uninfected persons perceiving that decom-
pensated cirrhosis and hepatocellular carcinoma causing the
most severe drop in utility. This information provides a means
of making a direct comparison between health states and esti-
